Tempest Therapeutics, Inc. announced the first patient has been dosed in the global randomized Phase Ib/II clinical study evaluating TPST-1120, Tempest’s small molecule PPAR⍺ antagonist, in combination with the standard-of-care regimen of atezolizumab and bevacizumab in the first-line treatment of patients with advanced or metastatic hepatocellular carcinoma.
[Tempest Therapeutics, Inc.]
7992332
{7992332:AAAAAAAA}
apa
50
1
167121
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/